학술논문
LACONORTE study: Efficacy and security of lacosamide as first add-on therapy for focal-onset epilepsy in real-life setting.
Document Type
Academic Journal
Author
Muñoz-Lopetegi A; Hospital Universitario Donostia, Department of Neurology, Paseo Dr. Beguiristain s/n, 20014, San Sebastián. Spain. Electronic address: amaia.munozlopetegi@osakidetza.eus.; López-González FJ; Complexo Hospitalario Universitario de Santiago, Department of Neurology, Rúa da Choupana, s/n, 15706 Santiago de Compostela, A Coruña, Spain. Electronic address: francisco.javier.lopez.gonzalez@sergas.es.; Rodríguez-Osorio X; Complexo Hospitalario Universitario de Santiago, Department of Neurology, Rúa da Choupana, s/n, 15706 Santiago de Compostela, A Coruña, Spain. Electronic address: xiana.rodriguez.osorio@sergas.es.; Pato Pato A; Hospital Povisa, Department of Neurology, Rúa de Salamanca, 5, 36211 Vigo, Spain. Electronic address: apato@povisa.es.; Bellas Lamas P; Hospital Alvaro Cunqueiro, Department of Neurology, Estrada de Clara Campoamor, 341, 36312 Vigo, Spain. Electronic address: paula.bellas.lamas@sergas.es.; Abella-Corral J; Complejo Hospitalario Universitario de Ferrol, Department of Neurology, Av. da Residencia, S/N, 15405 Ferrol, Spain. Electronic address: javier.abella.corral@sergas.es.; Castro Vilanova MD; Hospital Alvaro Cunqueiro, Department of Neurology, Estrada de Clara Campoamor, 341, 36312 Vigo, Spain. Electronic address: maria.dolores.castro.vilanova@sergas.es.; Garea MJ; Hospital Universitario del Río Hortega, Department of Neurology, Calle Dulzaina, 2, 47012 Valladolid, Spain. Electronic address: mgareag@saludcastillayleon.es.; Gil López JA; Paseo de Begoña 12, 3° Izq., 33201 Gijón, Spain. Electronic address: juangiltres@hotmail.com.; Ruiz-Martínez J; Hospital Universitario Donostia, Department of Neurology, Paseo Dr. Beguiristain s/n, 20014, San Sebastián. Spain. Electronic address: javier.ruizmartinez@osakidetza.eus.; Poza JJ; Hospital Universitario Donostia, Department of Neurology, Paseo Dr. Beguiristain s/n, 20014, San Sebastián. Spain. Electronic address: juanjose.pozaaldea@oskidetza.eus.
Source
Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8703089 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-6844 (Electronic) Linking ISSN: 09201211 NLM ISO Abbreviation: Epilepsy Res Subsets: MEDLINE
Subject
Language
English
Abstract
Rationale: Many patients with epilepsy need a second antiepileptic drug (AED), due either to inefficacy or side effects of the first tried one. We evaluated the efficacy and safety of lacosamide (LCM) as first add-on therapy in the real-life setting.
Methods: LACONORTE is a multicenter, retrospective, one-year study. Patients with focal epilepsy on monotherapy with another AED who were started on lacosamide as first add-on therapy were included. Clinical data was obtained at 3, 6 and 12 months and then analyzed.
Results: Seventy-three patients (48.6% men) with a mean age of 50.3 and a median duration of the epilepsy of 3.0 years (range 0-65) were included. At 1 year, 91.8% were responders (with at least 50% reduction in the number of seizures) and 64.4% of all patients and 75.8% of those with secondary generalization were seizure-free. Fifteen patients (20.5%) had adverse events (AE), most of them were transient and no severe AEs were reported. LCM was withdrawn in 2 patients due to intolerance and in 1 patient because of inefficacy. Neither side effects nor withdrawal seemed to be related to total dose or to escalating regimes. Seventy patients (95.9%) continued on LCM after the last visit (median dose 200 mg/day, ranging 100-400). Eighteen (24.7%) converted to monotherapy during the 12-month period, 83.3% of them remaining seizure-free.
Conclusions: These results of real-life setting show LCM to be efficacious and safe when used as first add-on therapy for focal-onset epilepsy. Most adverse events were mild and/or transient.
(Copyright © 2018 Elsevier B.V. All rights reserved.)
Methods: LACONORTE is a multicenter, retrospective, one-year study. Patients with focal epilepsy on monotherapy with another AED who were started on lacosamide as first add-on therapy were included. Clinical data was obtained at 3, 6 and 12 months and then analyzed.
Results: Seventy-three patients (48.6% men) with a mean age of 50.3 and a median duration of the epilepsy of 3.0 years (range 0-65) were included. At 1 year, 91.8% were responders (with at least 50% reduction in the number of seizures) and 64.4% of all patients and 75.8% of those with secondary generalization were seizure-free. Fifteen patients (20.5%) had adverse events (AE), most of them were transient and no severe AEs were reported. LCM was withdrawn in 2 patients due to intolerance and in 1 patient because of inefficacy. Neither side effects nor withdrawal seemed to be related to total dose or to escalating regimes. Seventy patients (95.9%) continued on LCM after the last visit (median dose 200 mg/day, ranging 100-400). Eighteen (24.7%) converted to monotherapy during the 12-month period, 83.3% of them remaining seizure-free.
Conclusions: These results of real-life setting show LCM to be efficacious and safe when used as first add-on therapy for focal-onset epilepsy. Most adverse events were mild and/or transient.
(Copyright © 2018 Elsevier B.V. All rights reserved.)